Home News Epicutaneous immunotherapy for peanut allergy found safe, tolerable through 5 years back to News
minute read
Treatment-emergent adverse events with epicutaneous immunotherapy for peanut allergy grew less frequent and severe over 5 years, according to a poster at the American Academy of Allergy, Asthma & Immunology Annual Meeting.
Topics: Press Coverage
13001 East 17th Place
Aurora, CO 80045
303.724.5375
© 2024 The Regents of the University of Colorado, a body corporate. All rights reserved.
Accredited by the Higher Learning Commission. All trademarks are registered property of the University. Used by permission only.
